Press release

Interim Report 1 January - 30 June 2009

· Treatment of the first cohort of 100 patients is completed in the phase ll study with product candidate TB-402, for the prevention of deep vein thrombosis (DVT). Recruitment of the second 100 patient cohort has been started.

· The phase I trial of BI-204 has been successfully completed. The product candidate to treat secondary cardiac events in patients with acute coronary syndrome was well tolerated. The drug is being co-developed with Genentech, Inc., a wholly-owned member of the Roche Group.

· Technology transfer under the terms of the alliance with Roche on product candidate TB-403 for the treatment of cancer has triggered a success fee of EUR 5 million to BioInvent and ThromboGenics.

· An application to initiate phase I trials of the product candidate BI-505 for the treatment of multiple myeloma has been submitted to the US Food and Drug Administration.

· Product candidate BI-505 has been granted orphan drug designation in Europe for the indication multiple myeloma. Equivalent status was previously granted in the US.

· Net revenues for January - June 2009: SEK 47.1 million (211.8 including initial milestone payment of 187.6 relating to TB-403).

· Current investments together with cash and bank as of 30 June 2009: SEK 150.5 million (121.7).

· Cash flow from current operations and investment activities for January - June 2009: SEK -61.9 million (-95.2).

· Loss after tax for January - June 2009 amounted to SEK -88.2 million (93.8) and the profit after tax per share was SEK -1.59 (1.68).

Contact
Any questions regarding this report will be answered by:
BioInvent International AB (publ.)
Svein Mathisen, President & CEO, tel.+46 (0)46 286 85 67, mobile +46 (0)708 97 82 13
Cristina Glad, Executive Vice President, tel. +46 (0)46 286 85 51, mobile +46 (0)708 16 85 70.

College Hill
Holly Griffiths, Sue Charles and John McIntyre, tel. +44 (0)20 7457 2020, [email protected]

The report is also available at www.bioinvent.com